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Esophageal squamouscell carcinoma(ESCC) isoneof themost commoncancersworldwideand thefourthmost lethal cancer inChina.How-
ever, althoughgenomic studieshave identifiedsomemutationsassociatedwithESCC,weknowlittleof themutationalprocesses responsible.
To identify genome-widemutational signatures, we performed either whole-genome sequencing (WGS) or whole-exome sequencing (WES)
on104ESCCindividuals andcombinedourdatawith thoseof88previously reportedsamples.AnAPOBEC-mediatedmutational signature in
47% of 192 tumors suggests that APOBEC-catalyzed deamination provides a source of DNA damage in ESCC. Moreover, PIK3CA hotspot
mutations (c.1624G>A [p.Glu542Lys] and c.1633G>A [p.Glu545Lys]) were enriched in APOBEC-signature tumors, and no smoking-
associated signature was observed in ESCC. In the samples analyzed by WGS, we identified focal (<100 kb) amplifications of CBX4 and
CBX8. Inourcombinedcohort,we identified frequent inactivatingmutations inAJUBA,ZNF750, andPTCH1and thechromatin-remodeling
genes CREBBP and BAP1, in addition to known mutations. Functional analyses suggest roles for several genes (CBX4, CBX8, AJUBA, and
ZNF750) in ESCC. Notably, high activity of hedgehog signaling and the PI3K pathway in approximately 60% of 104 ESCC tumors
indicates that therapies targeting these pathways might be particularly promising strategies for ESCC. Collectively, our data provide
comprehensive insights into the mutational signatures of ESCC and identify markers for early diagnosis and potential therapeutic targets.Introduction
Esophageal carcinoma (EC) is the eighth most common
and the sixth most lethal cancer worldwide. It tends to
have a very poor prognosis as a result of the limited clinical
approaches for early diagnosis1—the 5-year survival rate
ranges from 10% to 25%.1 Clinically, this heterogeneous
disease is categorized into two subtypes: esophageal adeno-
carcinoma (EAC) and esophageal squamous cell carcinoma
(ESCC).1 Approximately 70% of the worldwide cases of
ESCC occur in China, where the highest incidences are
in the Taihang Mountains of north-central China.1 The1Translational Medicine Research Center, Shanxi Medical University, Taiyuan,
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The Amrisk of developing ESCC in China has been linked to fac-
tors such as dietary habits (e.g., hot food and betelnut
chewing) and family history.2 Alcohol abuse and tobacco
consumption explain nearly 90% of ESCC cases inWestern
countries but represent minor factors in China.2
The processes of DNA damage and repair, which produce
the somatic mutations in a cancer genome, leave a signa-
ture of mutation.3 Recent analyses of comprehensivemuta-
tional catalogs from a malignant melanoma and a lung
cancer revealed the characteristic mutational patterns of
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mutations in ESCC and identified the ESCC-associated
genes ZNF750 (MIM 610226), FAT1 (MIM 600976), FAT2
(MIM 604269), and FAM135B,6,7 and point mutations in
genes such as PLCE1 (MIM 608414), XPF (MIM 133520),
ALDH2 (MIM 100650), and MTHFR (MIM 607093) show
different signatures between smokers and non-smokers
with ESCC.8–10 However, such studies have been limited
to a few genes, and it is unclear how representative these
findings are of mutational processes operative in ESCC
across the whole genome. In this study, we performed
whole-genome sequencing (WGS) of 14 and whole-exome
sequencing (WES) of 90 ESCC tumors and adjacent normal
tissue from individuals recruited from the Taihang Moun-
tains of north-central China and combined our data with
those of 88 previously reported samples to extract the
mutational signatures that cause somatic mutations in
ESCC and identify driver genes or pathways contributing
to this highly fetal disease in Chinese individuals.Material and Methods
Samples and Clinical Data
Tumor samples and adjacent, histologically normal tissues were
obtained from 104 ESCC-affected individuals recruited from the
Taihang Mountains of north-central China. All individuals gave
their informed consent, and all samples were obtained before
treatment according to the guidelines of the institutional review
board of Shanxi Medical University (approval no. 2009029) and
the ethics committee of Henan Cancer Hospital (approval no.
2009xjs12). The tumor samples of all affected individuals had at
least 40%–50% of tumor cell content. This study was approved
by the ethics committees of the Shanxi Medical University and
Henan Cancer Hospital. The ESCC individuals collected for this
study were staged according to the Cancer Staging Standards of
the American Joint Committee on Cancer (seventh edition,
2010). The cohort of 104 ESCC individuals included 96 smoking
and 8 non-smoking individuals. Different subsets of individuals
were assayed on each platform: 14 tumors and 14matched normal
samples had data available on WGS (653 coverage), and 90 sam-
ples had data available on WES (1323 coverage); in addition, 96
of the 104 samples had target capture deep resequencing (3653
coverage). A detailed description of the clinical characteristics of
the analyzed samples is presented in Table S1. We also analyzed
our previously published ESCC mutation dataset6 of 17 WGS
and 71 WES samples recruited from the Chaoshan District of
Gongdong Province, another area of high ESCC prevalence in
China. This cohort included 57 smoking and 31 non-smoking in-
dividuals.6 The summary of next-generation sequencing analyses
in this study is shown in Figure S1.Sequencing
For WGS, genomic DNAs extracted from 14 tumors and matched
normal tissues were randomly fragmented and purified. Standard
paired-end adaptors were ligated according to the manufacturer’s
(Illumina) protocol. Adaptor-ligated fragments were purified
with preparatory gel electrophoresis, and identical bands were
excised, resulting in two libraries per sample with inserts averaging
500 bp. Four lanes of each of the resultingWGS libraries were sub-
jected to WGS on an Illumina HiSeq 2000. Target depth (653 for598 The American Journal of Human Genetics 96, 597–611, April 2, 2tumors and normal samples) and at least 303 haploid coverage
were achieved in all samples.
For WES, the qualified genomic DNAs from 90 tumors and
matched normal tissues were randomly fragmented by Covaris,
ligated to Illumina sequenced adapters, and selected for lengths
from 150 to 200 bp. Extracted DNAs (150–200 bp) were then
amplified by ligation-mediated PCR (LM-PCR), purified, and hy-
bridized to the NimbleGen SeqCap EZ Exome (44M) array for
enrichment. Hybridized fragments were bound to the streptavidin
beads, whereas non-hybridized fragments were washed out after
24 hr.We then subjected captured LM-PCR products to the Agilent
2100 Bioanalyzer to estimate the magnitude of enrichment. We
independently loaded each captured library from the process
described above on three lanes of an Illumina HiSeq 2000 platform
with 90-bp paired-end reads for high-throughput sequencing to
ensure that each samplemet the desired average coverage. Raw im-
age files were processed by Illumina base-calling software (v.1.7)
with default parameters. The mean coverage achieved was 1303
in tumors and 1333 in normal tissue. A detailed description is pre-
sented in Table S2.Mutation Detection
For detection of somatic point mutations, sequencing reads from a
Illumina HiSeq 2000 were aligned to the human reference genome
(UCSC Genome Browser hg19) with the Burrows-Wheeler Aligner.
After duplicate reads (redundant information produced by PCR)
were removed with SAMtools, an in-house pipeline was used
to call somatic mutations. In brief, we implemented SAMtools
(v.0.1.18) and VarScan (v.2.2.5) to call somatic variants. We
required a minimum depth of 103 and variant frequency of
10% for both normal and tumor samples in order to call a specific
variant at that locus. A single-nucleotide variant (SNV) was labeled
highly confident if it met the following requirements: (1) the locus
was not enriched with reads of lowmapping quality, (2) reads that
supported the SNVwere not significantly overrepresented with ba-
ses of low quality, (3) reads that supported the SNV showed no bias
toward the read end, (4) no gaps were found near the SNV locus,
and (5) the SNV was not encompassed in short repeat regions.
The indel-calling step was performed by the Genome Analysis
Toolkit SomaticIndel Detector with default parameters. The highly
confident indels were identified by an in-house pipeline and
further annotated as germline or somatic on the basis of whether
any evidence of the event at the same locus was observed in the
normal data. Finally, highly confident SNVs were annotated
with ANNOVAR and used in follow-up analysis. A full list of muta-
tion events is presented in Table S3.Analysis of DNA Copy Number
To detect DNA copy-number alterations (CNAs), we performed
SegSeq11 to infer somatic CNA in ESCC genomes on the basis of
WGS reads. Copy numbers% 1.5 were considered to indicate de-
letions, and those R 2.5 were considered amplifications. To infer
recurrently amplified or deleted genomic regions, we re-imple-
mented the GISTIC algorithm12 by using copy numbers in 1-kb
windows as markers instead of SNP array probes. G-scores were
calculated for genomic and gene-coding regions on the basis of
the frequency and amplitude of amplification or deletion affecting
each gene. A significant CNA region was defined as having ampli-
fication or deletion with a G-score > 0.1, corresponding to a p
value threshold of 0.05 from the permutation-derived null distri-
bution. A full list of CNAs is presented in Table S4.015
Identification of Significantly Mutated Genes
To analyzemutation data and identify significantly mutated genes
(SMGs), we applied the analytical methodology MutSigCV (muta-
tion significancewith covariates) to facilitate the significance anal-
ysis with default parameters.
Pathway-Enrichment Analysis
We extended our significance analysis beyond single genes by
looking at gene sets. Pathway-enrichment analyses of genes with
non-synonymous mutations were performed with KEGG (Kyoto
Encyclopedia of Genes and Genomes) enrichment. In brief, we
performed the pathway-enrichment analysis with the Database
for Annotation, Visualization, and Integrated Discovery (v.6.7)
by examining the distribution of the non-synonymously mutated
genes identified within KEGG. Significantly altered pathways were
determined by p values calculated on the basis of hypergenometric
distribution with Benjamini correction.
Cell Lines
Normal esophageal epithelium cell lines SHEE and HEEPIC and
the following ESCC lines were used in this study: EC9706,
Eca109, TE1, TE12, TE13, Caes17, KYSE2, KYSE30, KYSE140,
KYSE150, KYSE410, KYSE510, KYSE450, and KYSE680. All were
tested and found to be free of mycoplasma contamination.
HEK293T cells were used as a packaging cell line to produce virus.
All cells were grown in DMEM with nutrient mixture F-12
(DMEM/F-12) supplemented with 10% fetal bovine serum at
37C in 5% CO2. Endogenous products encoded by the genes of
interest were detected through real-time PCR and/or immunoblot-
ting analyses. For functional analysis of special genes, the ESCC
lines with high endogenous gene expression were used for knock-
down experiments, and ESCC lines with low gene expression were
used for forced-expression experiments.
Knockdown and Overexpression of Genes of Interest
in ESCC Lines
Lentiviral vector pLKO.1-puro and its packaging plasmids
pMD2.G and psPAX2 were obtained from Addgene. Knockdown
experiments of the special genes were performed in at least two
ESCC lines with high endogenous protein levels. Two indepen-
dent short hairpin RNAs (shRNAs) were cloned into the pLKO.1-
puro vector as described previously.13 Specifically, to produce virus
production, titration, and infection lentiviruses, we transfected
HEK293Tcells with the packaging plasmids along with the lentivi-
ral shRNA vector by using Lipofectamine 2000 reagent (Invitro-
gen) according to the manufacturer’s instructions, and we
changed the medium after 6 hr. Virus was harvested 24 hr after
transfection, passed through 0.22-mm filters, and used fresh for
shRNA infection. To perform lentiviral infections, we plated the
target ESCC cells at 40%–50% confluence and incubated them
overnight (16 hr). On the day of infections, the culture medium
was replaced with the appropriately titered viral supernatant
(1.5 ml/well) and incubated at 37C for 24 hr; afterward, the viral
supernatant was replaced with fresh media. Forty-eight hours
later, infected cell populations were selected in puromycin
(2 mg/ml). After 5 days of selection, shRNA-knockdown efficiency
was determined by immunoblot analysis for the respective pro-
teins with the use of specific antibodies. For knockdown of special
genes in ESCC cells, two independent shRNA constructs that had
been cloned into the pLKO.1-puro vector were used (Table S5). A
non-specific targeting shRNA was also cloned into the pLKO.1-The Ampuro vector with the use of a scrambled control (SCR). Relative
amounts of special gene product were normalized to b-actin levels.
pMSCV-puro empty vector and wild-type pMSCV-puro-ZNF750
were generous gifts from Paul A. Khavari (Stanford University).
pcDNA3-RFP empty vector and wild-type pcDNA3-RFP-AJUBA
(MIM 609066) were generous gifts from Alejandra Garcia-Catta-
neo (National Heart and Lung Institute, Imperial College Lon-
don). The wild-type versions of these genes of interest were
cloned into the pLV-EGFP(2A)-puro-GFP vector and validated by
sequencing. For overexpression experiments, we used the pLV-
EGFP(2A)-puro-GFP vector as a control. Viruses were produced
as previously described. ESCC cells with low endogenous protein
levels were infected with viruses as previously described.14
Twenty-four hours after infection, cells were subjected to subse-
quent experiments. The mutants of genes of interest were gener-
ated with the QuikChange II Site-Directed Mutagenesis Kit
(Agilent).Fluorescence In Situ Hybridization Analysis
Tumor and matched normal tissues of ESCC individuals were cut
into pieces in PBS, swollen in 65 mmol/l KCl for 5 min at 37C,
fixed in cold acetic acid and methanol for 5 min at 4C, dropped
onto slides, and dried at room temperature. For interphase fluores-
cence in situ hybridization (FISH) analysis, slides were stained
with Cytocell enumeration probes against chromosomal region
5q, CBX8 (chr17: 77,768,175–77,770,915), or CBX4 (MIM
603079; chr17: 77,806,954–77,813,213). These probes were conju-
gated with fluorescein isothiocyanate (FITC) or Cy3.5 (Rainbow
Scientific). Probes against chromosomal region 5q or TMC8
(MIM 605829; located near the CBX4 and CBX8 regions) were
used as controls for verification of focal CNAs of CBX4 or CBX8.
Staining was carried out according to the manufacturer’s protocol.
FISH samples were viewed with a fully automated, upright Zeiss
Axio-ImagerZ.1 microscope with a 203 objective and DAPI,
FITC, and Rhodamine filter cubes. Images were produced with
the AxioCamMRmCCD camera and the Axiovision v.4.5 software
suite. p values were calculated with a two-sample test for equality
of proportions with continuity correction.qPCR Copy-Number Analysis
CBX4 and CBX8 copy number was assessed in seven frozen tumor
samples and matched normal tissues. Copy numbers were deter-
mined by real-time PCR with DNA binding dye SYBR Green I
with the use of specific primer pairs that flanked coding exons of
each gene. In a final volume of 25 ml, 20 ng DNA was amplified
with SYBR Green PCR Master Mix (QIAGEN) in triplicate. RPPH1
(ribonuclease P RNA component H1 [MIM 608513]; Life Technol-
ogies, 4403328) was used as a diploid control, and TMC8 (chr17:
76,126,858–76,139,049) was used as a control located in the re-
gion near genes CBX4 and CBX8. Data were analyzed via the
comparative (delta-Ct) Ct method.Immunoblotting
Cells were lysed for 30 min in Triton buffer (1% Triton X-100,
50 mM Tris-HCl, pH 7.6, 150 mMNaCl, 1% sodium deoxycholate,
and 0.1% SDS) supplemented with protease and phosphatase in-
hibitors (1 mM PMSF, 2 mM sodium pyrophosphate, 2 mM so-
diumbetaglycerophosphate, 1mM sodiumfluoride, 1mM sodium
orthovanadate, 10 mg/ml leupeptin, and 10 mg/ml aprotinin). Ly-
sates were cleared by centrifugation at 15,000 3 g at 4C for
15 min, and protein concentrations were determined by theerican Journal of Human Genetics 96, 597–611, April 2, 2015 599
Bradford method. Fifty micrograms of protein was separated by
SDS-PAGE and transferred onto Immobilon-P membranes. Pro-
teins were detected with special antibodies. Antibody binding
was detected with horseradish-peroxidase-labeled anti-mouse
(Sigma) or anti-rabbit (Cell Signaling) antibodies, and chemilumi-
nescence was detected with a LAS4000 device (Fuji). Equal protein
loading was confirmed with antibodies against b-actin (Transgen).
Detailed information on antibodies is shown in Table S5.
MTT Assay
A total of 43 103 cells were seeded in 96-well plates and incubated
in normal conditions for 24 hr. Cells were treated with 100 ml of
5 mg/ml of MTT (Invitrogen) solution for 4 hr at 37C until crys-
tals were formed. MTT solution was removed from each well, and
100 ml of DMSOwas added to eachwell to dissolve the crystals. Co-
lor intensity was measured by Microplate Reader (Bio-Rad) at
490 nm. Each experiment consisted of four replications, and at
least three independent experiments were carried out. For cell-
death analysis, cells were treated, in duplicate, with BKM120
(10 mM), GANT61 (20 mM) or both for up to 72 hr prior to flow
cytometric analysis for determining the extent of cell death by
Annexin V/PI staining.
Migration and Invasion Assays
Migration and invasion assays were performed in 16-well CIM
plates in an xCELLigence RTCA DP System (ACEA Biosciences)
with Matrigel Basement Membrane Matrix (BD) for real-time
cell-migration analysis as described previously.15 In brief, 30,000
cells per well were seeded as five duplicates in serum-free medium
at the upper compartment of the CIM plates coated with or
without Matrigel. Serum-complemented medium was added to
the lower compartment of the chamber, and then measurement
began in the xCELLigence RTCA DP system. We analyzed the
cell-index curves to determine cell-invasion activity. For negative
controls, we added serum-free medium at both upper and bottom
chambers. The cell index representing the amount of migrated
cells was calculated with RTCA Software from ACEA Biosciences.
At least three independent experiments were carried out; for
each independent experiment, five duplicates were performed
for each group.
Colony-Formation Assay
The assay was performed as described previously.16 In brief, cells
were seeded at 300–500 cells per well in 6-well plates containing
complete DMEM/F-12 on day 0 and incubated at 37C and 5%
CO2 for 10 days. On day 10, cells were fixed with 4% polyformal-
dehyde for 15 min and stained with 1% crystal violet before quan-
tification. The experiments were triplicated, and the numbers
of colonies containing more than 50 cells were microscopically
counted.
Real-Time qPCR
Real-time qPCR was used for measuring expression levels of genes
of interest in a subset of tumor samples or ESCC lines. The probes
or kits used in this study are shown in Table S5. All qPCR reactions
were performed in triplicate with an Applied Biosystems StepOne-
Plus. The relative expression of genes of interest was determined
by normalization to GAPDH expression via a standard-curve
method with ten serial dilutions according to the manufacturer’s
instructions. All real-time PCR experiments included a no-tem-
plate control and were done in triplicate.600 The American Journal of Human Genetics 96, 597–611, April 2, 2Immunohistochemistry Analysis
Immunohistochemistry was performed as previously described.17
In brief, sections were incubated with special antibody at an ideal
dilution for 14 hr at 4C and then detected with PV8000 (Zhong-
shan) and the DAB detection kit (Maixin), producing a dark-brown
precipitate. Slides were counterstained with hematoxylin. All im-
ages were captured at 1003. The nuclear amount of the protein
of interest was analyzed with Aperio Nuclear v.9 software, and
the cytoplasmic protein amount was quantified with Aperio Cyto-
plasma 2.0 software. Statistical analyses were performed with
GraphPad Prism 5.0. The staining intensity was scored as 0 (nega-
tive), 1 (weak), 2 (moderate), or 3 (strong). The immunoreactive
score (IRS) was determined by the product of the extent score
and the intensity score. IRS values ranged from 0 to 9, which
were graded as follows: 0 (negative), 1–3 (weak), 4–6 (moderate),
and 7–9 (strong). Themedian IRSwas chosen to define the individ-
uals, and the ratio of tumor to matched normal tissue (TIRS/NIRS)
was used to compare the protein of interest with significantly
high amounts (TIRS/NIRS > 2), high amounts (1 < TIRS/NIRS < 2),
low amounts (TIRS/NIRS< 1), or no change (TIRS/NIRS¼ 1) in tumor
tissue to that in matched normal tissue. All antibodies used in this
study are shown in Table S5.Mouse Xenograft Assay and Immunohistochemistry
To determine the effects of ZNF750 on tumorigenesis in vivo,
we used a mouse xenograft assay with 12- to 14-week-old
BALB/c nude female mice. We injected 2 3 106 KYSE150 cells sta-
bly depleted of ZNF750, scrambled control vector, wild-type
ZNF750, or p.Ser70* ZNF750 into nude mice (n ¼ 6 mice/group).
The growth rates of xenograft tumors were measured for 4 weeks,
after which mice were sacrificed. After 28 days, tumors were
removed, snap frozen in liquid nitrogen, and stored at –80C. Tu-
mor size was measured with calipers. Additionally, formalin-fixed
paraffin-embedded xenograft tumors were immunohistochemi-
cally stained with a monoclonal mouse Ki-67 antibody (Zhong-
shan). In brief, sections were incubated with the Ki67 antibody
working dilution for 14 hr at 4C and then detected with
PV8000 (Zhongshan) and the DAB detection kit (Maixin), produc-
ing a dark-brown precipitate. Slides were counterstained with he-
matoxylin. All images were captured at 203. The nuclear amount
of Ki-67 was analyzed with Aperio Nuclear v.9 software. Statistical
analyses were performed with GraphPad Prism 5.0.Statistical Analysis
The SPSS Statistics 17.0 package was employed to correlate clinical
and biological variables by means of Fisher’s test or a non-para-
metric test when necessary. Experiments were performed in tripli-
cate, and data were presented as mean 5 SD. Student’s t test was
used for statistical analysis, and data from more than two groups
were analyzed by one-way ANOVA in SPSS Statistics 19.0 and
a subsequent Fisher’s least significant difference t test. Results
were considered significant when p < 0.05. Association tests on
ZNF750 genotype and levels were performed on log-transformed
expression values by linear regression or t test.Results
Mutational Signatures of ESCC
To extract the mutational signatures that cause somatic
mutations in ESCC and identify driver genes or pathways015
Figure 1. Three Mutational Signatures
Identified in ESCC and Their Incidence
across the 192 Tumor Samples
(A) Ninety-six substitution classifications
from WGS or WES data derived from the
192 pairs of ESCC samples, including 88
samples from Song et al.6 Mutation types
are displayed in different colors on the hor-
izontal axis. The vertical axis depicts the
percentage of mutations attributed to a
specific mutation type.
(B) The contributions of mutational signa-
tures to individual tumors. Each bar repre-
sents a sample, and samples are ordered
by the proportion of signature A found in
them. The three mutational signatures
are represented by the different colors
shown in (A). For signature A, a significant
number of mutations in a sample is
defined as more than 100 substitutions in
total or more than 25% of all mutations
in that sample. Red or black triangles in-
dicate samples harboring the PIK3CA
c.1624G>A (p.Glu542Lys) or c.1633G>A
(p.Glu545Lys) mutation, respectively.
(C) Boxplot of the proportion of C>A
transversions in individuals with or
without a smoking history. Each dot repre-
sents the proportion of C>A mutations
in one individual; Student’s t test was
used to compare the difference between
the two groups. Data represent the
mean5 SD.contributing to ESCC inChinese individuals, we sequenced
the genome of 104 ESCC tumors and matched adjacent
normal tissues from individuals recruited from the Tai-
hang Mountains in north-central China (Table S1). WGS
(median coverage of 653) of 14 tumors and WES (me-
dian coverage of 1323) of 90 tumors were performed
(Figure S1). The average mutation rate was 3.9 coding mu-
tations/Mb in WGS samples and 2.4 non-silent mutations/The American Journal of HumaMb in WES samples (Table S2). This
rate is consistent with recently pub-
lished mutation rates in ESCC.6 A
high frequency of C>T transitions
was identified in the overall dataset18
(Figure S2A), and C>G transversions
occurred more frequently in ESCC
than in EAC19 (Figure S2B). We
selected candidate non-silent muta-
tions identified in 96 tumors for
validation by using the deep target
capture system (at least 3653). Valida-
tion rates were 97.8% for identified
SNVs and 58% for indels. We also
analyzed our previously published
ESCC mutation dataset6 of 17 WGS
and 71 WES samples recruited from
the Chaoshan District of Gongdong
Province, another area of high ESCC
prevalence in China (Figure S1E).To identify the mutational signatures within ESCC ge-
nomes, we applied the non-negative matrix-factorization
method20 to a combined mutation set of 192 ESCC tumors
(14WGS and 90WES samples from this study and 88 from
Song et al.6) and uncovered three mutational signatures
(Figure 1 and Figure S3). Signature A was characterized by
C>G, C>T, and C>A mutations at TpCpX trinucleotides
(suggesting collateral damage following DNA-elementn Genetics 96, 597–611, April 2, 2015 601
retrotransposition or exogenous viruses) and was associ-
ated with mutations in the APOBEC family of cytidine de-
aminases.21–25 Moreover, hotspot mutations (c.1624G>A
[p.Glu542Lys] and c.1633G>A [p.Glu545Lys]) on the
SMG PIK3CA (MIM 171834) were significantly enriched
in ESCC tumors that had an APOBEC signature (p ¼
0.0028, Fisher’s exact test, one-sided), implicating APOBEC
activity as a key driver of PIK3CA mutagenesis in ESCC.
Signature B was characterized by an enrichment of C>T
mutations at XpCpG trinucleotides as a result of an
elevated rate of spontaneous 5-methyl-cytosine deami-
nation.26 The elevated C>T mutation rate at XpCpG
trinucleotides is a well-recognized mutational mechanism
probably due to deamination to thymine ofmethylated cy-
tosines, which are usually at XpCpGs.26 Signature C was
represented by types that, to our knowledge, are not yet
known.
Tobacco smoking is consistently reported as an impor-
tant risk factor for esophageal cancer, especially for
squamous cell carcinoma27 and gastric cancer.28 The com-
bined cohort of 192 ESCC individuals (104 from this
study and 88 from Song et al.6) included 153 smoking
and 39 non-smoking individuals (Table S1). Notably,
we observed no smoking-associated signature character-
ized by C>A mutations, which was defined by Alexandrov
et al.,29 within ESCC genomes. Furthermore, we com-
pared the proportion of C>A transversions between
smoking and non-smoking individuals and observed
no statistically significant difference (p ¼ 0.687, Fig-
ure 1C). Additionally, we found no smoking-associated
signature in 149 EACs (at least 49 of 149 individuals
with a history of smoking) from a pan-cancer study.19,29
These results indicate that the smoking-associated signa-
ture of C>A mutations is limited in EC. Considering
that epidemiological studies suggest that tobacco con-
sumption might be associated with EC,30 we speculate
that other smoking-associated signatures that have
not been recognized might contribute to malignancy of
ESCC.
CNAs of ESCC
To investigate somatic CNAs in ESCC, we applied a modi-
fied GISTIC method to profile genome segments with
CNAs in the 14 WGS tumors (Figure S4A). This analysis
yielded 126 significantly altered regions (Table S4). One
of the most significantly altered regions, 3q26.1–q29,
contains SOX2 (MIM 184429), encoding a member of the
SRY-related HMG-box family of transcription factors in-
volved in embryonic development regulation and in cell-
fate determination.31 This gene is overexpressed in ESCC
and associated with chemoresistance. Downregulation of
SOX2 might inhibit ESCC tumorigenesis and increase
sensitivity to chemotherapy.32 Notably, of the nine tumors
harboring SOX2 amplifications, we observed one focal
(defined as <100 kb) CNA containing only SOX2
(Figure S5), indicating that SOX2 is the most likely target
of 3q26 amplification in ESCC.602 The American Journal of Human Genetics 96, 597–611, April 2, 2Focal CNAs are more likely to contain driver genes that
confer clonal advantage, are causally implicated in onco-
genesis, and have been positively selected during the
evolution of the cancer.33 Therefore, to identify genes
affected by recurrent CNAs, we used the Integrative Geno-
mics Viewer to manually inspect the 126 significantly
altered regions. This approach identified recurrent focal
CNAs, including amplified chromosomal segments con-
taining CBX4 and CBX834,35 (Figure S4B). Amplification
of these genes was validated by FISH and qPCR copy-
number assay (Figure 2A). Of the 104 ESCC specimens,
39% and 51% of tumors had an immunoreactivity score
for CBX4 and CBX8 levels, respectively, which is at least
double that of matched normal tissue (TIRS/NIRS > 2;
Figure 2B). Moreover, silencing CBX4 and CBX8 in
KYSE2 and KYSE510 cells (which harbor high endoge-
nous expression) significantly inhibited cell proliferation,
colony formation, and cell invasion (Figures 2C–2E;
Figure S6). These results suggest that CBX4 and CBX8
amplification and the resultant protein upregulation
contribute to the development of ESCC and that they
might thus serve as potential drug targets for ESCC
treatment.
SMGs
We next applied the MutSigCV method36 to identify
SMGs in the combined 192 ESCC tumors (Figure S1E)
and discovered nine such genes driven by point muta-
tions (false discovery rate, q < 0.1) and six further genes
with p < 0.01 (Figure 3A). Eleven of these 15 genes—
including AJUBA, ZNF750, FAT1, FBXW7 (MIM 606278),
and PTCH1 (MIM 601309) and the chromatin-remodeling
genes CREBBP (MIM 600140) and BAP1 (MIM 603089)—
harbored frequent inactivating mutations. Although
AJUBA, ZNF750, FAT1, and FBXW7 were recently impli-
cated as tumor suppressors in ESCC,7,37 their roles in
mice models and the mechanisms by which they function
as tumor suppressors are limited. As in other cancers,38,39
particularly EAC,19 this analysis also identified well-known
cancer-associated genes, such as TP53 (MIM 191170),
PIK3CA, and CDKN2A (MIM 600160), as SMGs in ESCC,
thus providing evidence of common dysfunctions in cell-
cycle control and apoptotic signaling.
AJUBA, which encodes a LIM domain protein, in-
hibits the ATR-dependent DNA-damage response and is
involved in several cellular processes, such as cell-fate
determination, cytoskeletal organization, transcriptional
repression, mitotic commitment, cell-cell adhesion, and
migration.40 Along with LIMD1 (MIM 604543), AJUBA
has been proposed to be a major component of the
miRNA-mediated gene-silencing machinery and might
have a tumor-suppressive function.41 However, the bio-
logical functions of AJUBA in ESCC tumorigenesis have
never been reported. The following AJUBA mutations
were identified and verified in four tumor samples:
two stop-gain mutations (c.985G>T [p.Glu329*] and
c.1057C>T [p.Gln353*]) and two frameshift indels015
Figure 2. Amplified Genes Identified in ESCC by GISTIC
(A) CBX4 and CBX8were amplified in ESCC tumors. Left panel: immunofluorescence images show signals produced from FISH analyses
using probes specific to chromosomal region 5q (red, control) and CBX4 or CBX8 (green) in ESCC samples 3N09 and 3T09. Scale bars
represent 5 mm. Right panel: CBX4 and CBX8 copy number was assayed by qPCR in 3N09 and 3T09. RPPH1 was used as a normal refer-
ence, and TMC8 (located near this region) was used as a focal CNA control. Data represent the mean5 SD. All assays were performed in
triplicate.
(B) The amounts of CBX4 and CBX8 were increased in ESCC tumors. Representative immunohistochemistry images show CBX4 or
CBX8 levels in the same tumor. The bar graph shows the percentage of indicated individuals with different CBX4 or CBX8 levels in
the 104-individual ESCC cohort. CBX4 or CBX8 levels were based on subjective assessment of immunohistochemical staining intensity
(see Material and Methods). Scale bars represent 400 mm.
(C–E) Depletion of CBX8 in KYSE2 and KYSE510 cells significantly inhibited cell proliferation, as measured by MTT assay (C), colony-
formation assays (D), and cell invasion (E). Knockdown ofCBX8 is demonstrated by immunoblotting (bottomof C); b-actinwas used as a
loading control. Data represent the mean5 SD. At least three independent experiments were performed in triplicate. Statistical analysis
was performed with a two-sided t test. **p < 0.01, *p < 0.05.(c.790_791insT [p.Val264fs*] and c.152delG [p.Gly51fs*])
in the 104-individual cohort and one frameshift insertion
(c.1249_1250insA [p.Ala417fs*]) and one splice-site muta-
tion in two individuals from our previous cohort6
(Figure 3B; Figure S7A; Table S3). These mutational events
result in truncated or disrupted protein products that lack
proper LIM domains, indicating that they are loss-of-func-
tion mutations, and these mutations in AJUBA, encoding
the truncated or disrupted protein, are expected to pro-
mote ESCC oncogenesis. In support of this possibility,
immunoblot analysis showed the presence of truncated
AJUBA in ESCC tumors (Figure 4A). AJUBA knockdown
in KYSE140 and KYSE510 cells led to increased cell
growth, colony formation, cell migration, and cell inva-
sion (Figure S8). Moreover, exogenous levels of wild-type
AJUBA in KYSE30 and KYSE150 cells with low endoge-
nous AJUBA levels suppressed cell growth, cell migration,
and cell invasion; these effects were abrogated by AJUBA
alterations (p.Gln353* and p.Val264fs*; Figures 4B–4F).
Together with our genetic observations, these functional
data indicate that AJUBA might act as a tumor suppressorThe Amin ESCC and that the AJUBA mutations observed in ESCC
abrogate its tumor-suppressive function.
Mutations in ZNF750, a tumor-associated gene located at
17q25,7 were identified in 6% of ESCC tumors. We identi-
fied 11 somatic mutations, of which we verified (via
Sanger sequencing) six, including two nonsense mutations
(c.620G>A [p.Trp207*] and c.209C>A [p.Ser70*]), one indel
(c.108_111del [p.Glu37Lysfs*]), and three missense muta-
tions (c.96T>A [p.Phe32Leu], c.1520A>C [p.Asp507Ala],
and c.1508C>G [p.Ser503Cys]) in ZNF750 in the 104-indi-
vidual cohort. In addition, five (c.414C>A [p.Cys138*],
c.770C>A [p.Ser257*], c.85C>T [p.Gln29*], c.625_626in-
sAA [p.Ala209fs*], and c.1621G>A [p.Ala541Thr]) out of
11 somatic mutations were verified by Sanger sequencing
in our previous cohort6 (n ¼ 88; Figure 3B). Sixty-four
percent of themutations identified inZNF750 are inactivat-
ing. Additionally, ZNF750 deletions, but no somatic muta-
tions, were observed in 3 out of 14 tumor samples in the
WGS set (21%, G-score > 0.23) and validated with a qPCR
copy-number assay. The qPCR copy-number assay also
determined that four out of six tumor samples harboringerican Journal of Human Genetics 96, 597–611, April 2, 2015 603
Figure 3. Somatic Mutations of Candidate Cancer-Associated Genes, Ranked by Significance across 192 Tumors
(A) Candidate driver genes were identified via MutSigCV significance analysis. The gray histogram at the top shows the number of mu-
tations per megabase in each sample, and each rectangle represents 1 Mb. Themain section shows each mutation type for every sample,
including the total number of mutated samples per gene; mutation subtypes are denoted by color. If multiple mutations were observed
within a gene in a single sample, only one is shown. The candidate cancer-associated genes are shown on the left: genes marked by an
asterisk have a q value of <0.1. The bottom three rows indicate smoking status, drinking status, and family history. NA means that the
condition remains unknown, and ‘‘positive’’ means that the individual has the condition shown on the left. The full list of mutated
genes is provided in Table S3.
(B) A schematic representation of the domain structure of proteins (ZNF750, AJUBA, FAT1, NFE2L2, PTCH1, SUFU, CREBBP, and BAP1)
encoded by SMGs shows the location of somatic variants identified in ESCC tumors. DNAmutations and amino acid changes are shown.
The C-terminal nuclear localization sequence (NLS) of ZNF750 is shown in black.ZNF750mutations or indels in the 90-sampleWES set were
affected bydeletions, indicating that inactivationof both al-
leles had occurred in these individuals (Figures S9A–S9C).
Notably, frequent loss of heterozygosity at 17q25.3 has
been previously reported in ESCC,42 but no gene at or near
the 17q25.3 regionwas identified.Our genetic data strongly
indicate that ZNF750 is the missing piece of this puzzle.
We next used the immunohistochemical method to
determine whether a correlation exists between these ge-
netic changes and the amount of ZNF750. As expected,
ZNF750, a nuclear factor, was strongly stained in the
nuclei of normal esophageal epithelial cells. Surprisingly,604 The American Journal of Human Genetics 96, 597–611, April 2, 2though, it was dramatically upregulated in the cytoplasm
of ESCC tumor cells in comparison to that of normal
tissue cells. Moreover, individuals with tumors harboring
ZNF750 mutations had higher cytoplasmic expres-
sion levels than did those lacking ZNF750 mutations
(Figure 5A). Mislocalization of a truncated (p.Ser70*)
ZNF750 (Figure 5B) indicated that cytoplasm transloca-
tion was partly caused by loss of the C-terminal nuclear
localization sequence. ZNF750 regulates the gene pro-
gram controlling terminal epidermal differentiation.43
For investigating a function for ZNF750 in tumorigenesis,
shRNA-mediated stable ZNF750 depletion was followed015
Figure 4. AJUBA Acts as a Tumor Suppressor in ESCC
(A) Immunoblotting validation of truncated AJUBA proteins in two identified ESCC tumors.
(B–F) The effect of wild-type and altered AJUBA on cell growth, cell migration, and cell invasion, as monitored byMTTassay (C), colony-
formation assay (D), and cell-migration and cell-invasion assays in an xCELLigence RTCADP system (E and F). The presence of wild-type
AJUBA or AJUBA altered by p.Gln353* (p.Q353X) or p.Val264fs* (p.V264fs) in KYSE30 and KYSE150 cells was confirmed by immuno-
blotting with anti-AJUBA antibody, which recognizes the N terminus of AJUBA (B). These cell lines all have a low level of endogenous
AJUBA.
Data represent the mean5 SD; three independent experiments were performed in triplicate. Statistical analysis was performed with a
two-sided t test. **p < 0.01, *p < 0.05.by transfection with wild-type or altered (p.Ser70* or
p.Trp207*) ZNF750 in KYSE150 and KYSE140 cells.
ZNF750 knockdown strongly promoted KYSE150 and
KYSE140 cell proliferation, migration, and invasion.
Moreover, functional studies demonstrated that wild-
type ZNF750 inhibited cell growth, migration, and inva-
sion, and this effect was abrogated by altered (p.Ser70*
or p.Trp207*) ZNF750 (Figure 5C; Figures S9D and S9E).
Finally, ZNF750 depletion and p.Ser70* ZNF750 mar-
kedly increased tumor size in the xenograft system inThe Ammice, whereas wild-type ZNF750 significantly decreased
it (Figure 5D). Our genetic observations and functional
data therefore suggest that ZNF750 acts as a tumor sup-
pressor in ESCC.
FAT1, which encodes a cadherin-like protein commonly
expressed in epithelial tissues,44 was mutated in 15%
of ESCC tumors. Notably, 13 mutations (77%) were trun-
cating (stop-gain and frameshift) (Table S3). FAT1 is
reported to regulate cell-cell adhesion and other cell
behavior by controlling actin polymerization.44 Recently,erican Journal of Human Genetics 96, 597–611, April 2, 2015 605
Figure 5. ZNF750 Acts as a Tumor Suppressor in ESCC
(A) Immunohistochemical analysis shows ZNF750 staining in esophageal tissues and matched normal tissue of ESCC-affected individ-
uals harboringwild-type ZNF750 (ZNF750-WT, second row) or nonsynonymous alterations (ZNF750-nonsynonmyous, third row). Nega-
tive and positive controls are normal skin samples (first row). Graphs (right) show nuclear (top) and cytoplasmic (bottom) amounts of
ZNF750 in ESCC and normal esophageal tissue on the basis of a subjective assessment of immunohistochemical staining intensity (see
Material and Methods, c2 test, **p < 0.01, *p < 0.05). Scale bars represent 400 mm.
(legend continued on next page)
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Morris et al. reported that FAT1 suppresses cancer cell
growth by binding b-catenin and preventing nuclear local-
ization.44 FAT1 inactivation, via mutations that affect
the cytoplasmic domain, leads to aberrant Wnt/b-catenin
signaling in multiple cancer types.45 In our cohort, we
discovered mutations affecting cadherin repeats and lami-
nin G domains but nomutations affecting the cytoplasmic
domain. This observation indicates that mutations
affecting FAT1 extracellular domains might disrupt cell-
cell associations and increase invasiveness and thus
potentially contribute to ESCC tumorigenesis. FBXW7mu-
tations were observed in eight ESCC tumors in our cohort:
these included two nonsense mutations (c.1005T>A
[p.Cys335*] and c.409G>T [p.Glu137*]), one frameshift
deletion (c.736_739del [p.Gly247Profs*] and inactivating
mutations), and five missense mutations predicted to be
deleterious by SIFT and PolyPhen-2 analyses (Table S3).46
FBXW7 mutations and copy-number loss and a subse-
quent decreased FBXW7 level have been observed in
various cancer types.46,47 Decreased amounts of FBXW7
are reported to correlate with poor prognosis;47 however,
we observed no correlation between FBXW7 mutations
and prognosis in our cohort.
Inactivating mutations in several chromatin-remodeling
genes, including CREBBP and BAP1, frequently occurred in
our 104 ESCC samples. CREBBP and EP300 (MIM 602700)
mutations occurred in 11/104 ESCC tumors (Table S3).
Inactivating CREBBP and EP300 mutations have been
reported in various human cancer types.6,48 We also
identifiedmutations in BAP1, which encodes a nuclear deu-
biquitinase involved in chromatin remodeling.49 BAP1mu-
tations have been reported in renal carcinoma and uveal
melanoma,49 but not in ESCC to date. Moreover, frequent
truncating mutations were observed in the chromatin-
remodeling genes KMT2D (MLL2 [MIM 602113]) and
KMT2C (MLL3 [MIM 606833]) (14% together) and KDM6A
(MIM 300128) (3%) (Table S3). At least one chromatin-re-
modeling gene was altered in 33/104 ESCC tumors.
Altered Pathways in ESCC
In our screen, SMGswere enriched in four pathways known
to be important in cancer, including the cell cycle,
NOTCH signaling, PI3K signaling, and cell adhesion. In
addition, analyses of theKEGGpathway revealed overrepre-
sented mutations of hedgehog (Hh) signaling and MAPK
signaling, and a high percentage of truncating mutations(B) Immunofluorescence of FLAG-tagged wild-type ZNF750 (ZNF750-
ond and fourth rows) in KYSE150 (top) and KYSE140 (bottom) cells.
(C) Endogenous ZNF750 was stably knocked down in KYSE150 and
ZNF750 (ZNF750-WT) or the p.Ser70* (ZNF750-S70X) or p.Trp207* (
ony-formation assay. SCR indicates scramble control. The data repr
formed in triplicate. Data were statistically analyzed by a two-sided t
(D) Tumor xenografts show significant growth inhibition of cells ov
(from top to bottom) the SCR vector control, ZNF750 knockdown (ZN
(ZNF750-S70X) (n ¼ 6 per group). The graph at the bottom left sho
also shown (in the images on the right [the scale bar represents 2
mean5 SD. **p < 0.01, *p < 0.05.
The Amwere observed in chromatin-remodeling genes (Figure 6A).
Eleven recurrent mutated genes involving the cell-cycle
regulatory pathway were identified, and TP53, CDKN2A,
and RB1 (MIM 614041) accounted for 88%, 8%, and 2%,
respectively (Table S3). Moreover, frequent truncating
mutations were observed in KMT2D and KMT2C (14%),
CREBBP and EP300 (13%), and KDM6A (3%). Genes
involved in the PI3K-AKT-mTOR pathway were mutated in
29% of 104 tumors, and PIK3CAwas the most significantly
altered gene (17%). Immunohistochemical analysis con-
firmed the presence of PIK3CA, AKT1, and GLI1 in tumors
(comparedwithmatched normal tissue) in the 104-individ-
ual WGS and WES cohorts (Figure 6B). Hence, these data
shed light on the essential role of dysregulation of these
critical pathways in tumorigenesis of ESCC.Discussion
In this study, we report the detailed, next-generation anal-
ysis of mutational processes underlying ESCC. By com-
bining our findings with a previous dataset, we found three
genome-wide mutational signatures for ESCC. Notably, an
APOBEC-mediated mutational signature indicates that
the APOBEC family might get access to the nucleus and
cause ESCC-associated genomic damage or mutation. The
APOBEC family can deaminate cytosine to uracil within
DNA, leading to mutation clusters in various types of can-
cer.22 Several APOBEC family members have access to the
nuclear compartment and can impede the cell cycle,
most likely through DNA deamination and the ensuing
DNA-damage response. Such genomic damage might
contribute to carcinogenesis.23,24 APOBEC3B, acting on
lentiviral replication intermediates constituting an innate
pathway of antiretroviral defense,24,25 was reported to be
present in high amounts in ESCC,7 suggesting that it
might be an attractive candidate for the mechanisms un-
derlying mutation signature A in ESCC. In our cohort
and that from Song et al.,6 at least 47% of ESCC tumors
had an APOBEC signature, suggesting that APOBEC-cata-
lyzed genomic uracil lesions are responsible for a large pro-
portion ofmutations in ESCC. Thus, the APOBEC signature
might be a potential oncogenic pathway underlying muta-
tional mechanisms in ESCC development.
Moreover, we identified several significantly amplified
focal CNAs containing two ESCC-associated genes (CBX4WT, first and third rows) and p.Ser70* ZNF750 (ZNF750-S70X, sec-
DAPI labels the nucleus. Scale bars represent 10 mm.
KYSE140 cells and then forced to encode FLAG-tagged wild-type
ZNF750-W207X) variant. Cell proliferation was monitored by col-
esent the mean 5 SD; three independent experiments were per-
test. **p < 0.01, *p < 0.05.
erexpressing WT ZNF750. Five representative tumors are shown:
F750-si), wild-type ZNF750 (ZNF750-WT), and the p.Ser70* variant
ws tumor volumes. Immunohistochemical analyses of Ki-67 are
00 mm] and the graph at the bottom right). Data represent the
erican Journal of Human Genetics 96, 597–611, April 2, 2015 607
Figure 6. Altered Pathways in ESCC
(A) Key cancer pathway components altered in ESCC. ESCC potential driver genes and their mutation frequencies were mapped to the
followingmajor groups: NOTCH signaling, PI3K pathway, p53 pathway, Hh pathway, MAPK pathway, chromatin remodeling, and regu-
lation of cell adhesion. Alteration frequencies are shown as a percentage of those in all samples; genes identified as SMGs by the Mut-
SigCV analytical method are colored in red. Excitatory (arrows) and inhibitory (black lines) interactions were taken from the KEGG
pathway database.
(B) Representative immunohistochemistry images show PIK3CA, AKT1, or GLI1 levels in tumors and matched normal tissues. The bar
graph shows PIK3CA, AKT1, or GLI1 levels on the basis of a subjective assessment of immunohistochemical staining intensity. Scale bars
represent 400 mm.and CBX8) not previously observed in ESCC. CBX4 and
CBX8 are major transcriptional repressors that epigeneti-
cally modify chromatin and exert important functions in
cell-cycle regulation, DNA repair, cell differentiation, cell
senescence, and cell death.34 CBX4 and CBX8 expression
has been demonstrated to be upregulated in certain types
of human cancer.35 However, their amplification and bio-
logical roles have not previously been reported in ESCC.608 The American Journal of Human Genetics 96, 597–611, April 2, 2Our functional and clinical analyses indicate that these
genes might act as oncogenes in ESCC and thus represent
potential therapeutic targets.
In addition to identifying the well-defined cancer-associ-
ated genes TP53, NOTCH1 (MIM 190198), PIK3CA, RB1,
CDKN2A, and FBXW7, we identified recently implicated
ESCC-associated genes AJUBA, ZNF750, and FAT1 in our
combined cohort. Recently, pan-cancer studies across 21015
cancer types predicted that AJUBA and ZNF750, two SMGs
in our cohort, are associated with some types of cancer.50
Using functional studies, we found that AJUBA and
ZNF750 (previously known but with unknown function
in ESCC) act as tumor suppressors and that mutations in
these genes abrogated their tumor-suppressive effects.
Therefore, AJUBA and ZNF750 mutations encoding trun-
cated or disrupted proteins might contribute to ESCC
tumorigenesis.
Our previously published paper identified TP53, RB1,
CDKN2A, PIK3CA, NOTCH1, NFE2L2 (MIM 600492),
ADAM29 (MIM 604778), and FAM135B as SMGs on the ba-
sis of the dataset of WGS in 17 ESCC individuals and WES
in 71 individuals recruited from the Chaoshan District of
Guangdong Province, an area of high ESCC prevalence
in southern China.6 In this study, in addition to identi-
fying TP53, PIK3CA, NOTCH1, and CDKN2A, which have
been implicated previously, we further identified FBXW7,
FAT1, AJUBA, and ZNF750 as SMGs from the dataset of
WGS in 14 ESCC individuals andWES in 90 individuals re-
cruited from Shanxi and Henan provinces in the Taihang
Mountains, an area of high ESCC prevalence in northern
China. When we combined these two cohorts, we identi-
fied more SMGs, including PTCH1 and the chromatin-re-
modeling genes CREBBP and BAP1. Of these SMGs, AJUBA,
ZNF750, FAT1, and FBXW7 were identified in ESCC indi-
viduals recruited from northern China, but not in those
from southern China, which was confirmed in the cohorts
from Lin et al.7 and Gao et al.37 (individuals in their co-
horts were from the Cancer Institute and Hospital of the
Chinese Academy of Medical Sciences, where individuals
are mostly from northern China). Epidemiologic studies
have shown that in addition to smoking, alcohol con-
sumption, and family history, the known risk factors for
ESCC were thought to be hot food and N-nitroso com-
pounds in northern China, whereas chewing of fermented
areca nut has been shown to be independently associated
with ESCC in southern China.1,2 We speculate that the
different environmental carcinogens (e.g., dietary and life-
style patterns) between northern and southern China
might cause genetic diversity in ESCC individuals.
In summary, we used genomics data to pinpoint the
predominant underlying mutational processes linked to
ESCC. A signature attributed to the APOBEC family of cyti-
dine deaminases was predominant in ESCC individuals,
reflecting that this gene family contributes to cytosine mu-
tation clusters in ESCC and cancer susceptibility through
APOBEC-dependent mutational processes. Unlike the situ-
ation with lung cancer, smoking tobacco was not strongly
associated with ESCC in the Chinese population, giving in-
sights into the mutational burden not associated with this
lifestyle choice. Furthermore, we have provided functional
evidence of inactivating mutations in AJUBA and ZNF750,
amplification of CBX4 and CBX8, and genomic aberrations
targeting the cell cycle and NOTCH, PI3K, and Hh sig-
naling pathways. These results highlight the substantial
genetic alterations contributing to ESCC tumorigenesisThe Amand provide a set of potential therapeutic targets toward
its prevention and chemotherapies. Further studies are
required to explore how APOBEC family members and
oncogenic ZNF750, AJUBA, CBX4, and CBX8 contribute
to mutagenesis in ESCC, whether these genes are prom-
ising for drug discovery, and whether the therapies target-
ing PI3K and/or Hh signaling pathways are particularly
promising strategies for ESCC.Accession Numbers
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